

Instructions to the Authors

[General Information](#) | [Article Processing Charges](#) | [Prepare main manuscript](#) | [Illustrations and Figures](#) | [Preparing tables](#) | [Ad language](#) | [Download Instructions](#)

✓ General information

Before you submit your manuscript, please note that the Journal of Carcinogenesis is an open access journal and operates on "Authors pay" model.

Partial waivers may be granted at the discretion of the executive editor. Please contact the editorial office (editor@carcinogenesis.com) for details before you submit your manuscript. Please send a brief abstract of your proposed manuscript along with your request for partial waivers.

Manuscripts must be submitted online only by one of the authors of the manuscript. The submitting author takes responsibility for the peer review. The submitting authors accept responsibility for getting the approval from all the authors and keeping them informed.

Files can be submitted as a batch, or one by one. The submission process can be interrupted at any time - when users return they left off.

See below for examples of acceptable word processor and graphics file formats. Additional files of any type, such as movies, can also be submitted as part of the publication.

During submission you will be asked to provide a cover letter. Please use this to explain why your manuscript should be published and any issues relating to our editorial policies detailed in the instructions for authors.

Assistance with the process of manuscript preparation and submission is available from the customer support team (editor@carcinogenesis.com).

Publication and peer review processes

Journal of Carcinogenesis uses online peer review to speed up the publication process. The time taken to reach a final decision, request revisions, and how quickly authors are able to respond.

Once an article is accepted, it is published in Journal of Carcinogenesis immediately as a provisional PDF file. The paper will be available in a browse-able web form, and as a formatted PDF; the article will then be available through Journal of Carcinogenesis, and PubMed.

The ultimate responsibility for any decision lies with the Executive Editor to whom any appeals against rejection should be addressed.

Article-processing charges

Journal of Carcinogenesis levies an article-processing charge for every accepted article. In 2008 the article-processing charge is £800. Waivers may be granted at the discretion of the executive editor. Please contact the editorial office (editor @ carcinogenesis . org) for details of your manuscript.

Editorial policies

Any manuscript submitted to the journal must not already have been published in another journal or be under consideration elsewhere or have been deposited on a preprint server. Manuscripts must not have already been published in any journal or other citable form. The journal is willing to consider peer-reviewing manuscripts that are translations of articles originally published in another language. The journal in which the article was originally published must be obtained and the fact that the article has already been published must be stated in the abstract. Manuscripts that are derived from papers presented at conferences can be submitted unless they have already appeared in conference proceedings in a peer reviewed journal. Authors are required to ensure that no material submitted as part of a manuscript infringes on the rights of a third party.

Authors who publish in Journal of Carcinogenesis retain the right to print and share their work with colleagues for academic purposes but not to allow anyone else to sell their work. The authors grant rights to Carcinogenesis Press to distribute the reprints/ print versions of their work at no cost to anyone who likes to receive them. Carcinogenesis Press may also make the printed version of journal available to individuals. Authors will not be entitled to any royalty from any sales by Carcinogenesis Press.

Submission of a manuscript to Journal of Carcinogenesis implies that all authors have read and agreed to its content, and that the research reported in the manuscript has been performed with the approval of an appropriate ethics committee. Research carried out on humans must follow the Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement of approval must be included in the Methods section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. Manuscripts may be rejected if the editorial office considers that the research has not been carried out within the guidelines or the severity of the experimental procedure is not justified by the value of the knowledge gained.

Copyright form should not be uploaded as an image/article file; it can be part of the first page file or send it via email to the editorial office.

Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in parentheses.

We ask authors of Journal of Carcinogenesis papers to complete a declaration of competing interests, which should be provided with the manuscript. Where an author gives no competing interests, the listing will read 'The author(s) declare no competing interests.'

competing interests. The following articles provide some background competing interests:

R Smith: Beyond conflict of interest. *BMJ* 1998, 317 :291-292

R Smith: Making progress with competing interests. *BMJ* 2002, 325 :1375-1376

CD DeAngelis, PB Fontanarosa, A Flanagin: Reporting financial conflicts of interest and relationships between investigators and patients. *JAMA* 2000, 283 :89-9

K Morin, H Rakatansky, FA Riddick Jr, LJ Morse, JM O'Bannon 3rd, MS Goldrich, P Ray, M Weiss, RM Sade, MA Spillman: Management of clinical trials. *JAMA* 2002, 287 :78-84

For all articles that include information or clinical photographs relating to individual patients, written and signed consent from the patient or their relative must be obtained and mailed or faxed to the editorial staff. The manuscript should also include a statement to this effect in the Acknowledgements section: "Consent for publication was obtained from the patient or their relative."

Journal of Carcinogenesis supports initiatives to improve the performance and reporting of clinical trials, part of which includes the numbering of trials. While there are initiatives to ensure that all clinical trials are registered (most notably the recent statement from the International Medical Journal Editors - see http://www.icmje.org/clin_trialup.htm), we are focussing on controlled trials of healthcare interventions. Reports of controlled trials of health care interventions must register their trial prior to submission in a suitable publicly accessible database. The guidelines currently meet all of the ICMJE guidelines can be found at <http://www.icmje.org/faq.pdf>.

The trial registration number should be included as the last line of the abstract of the manuscript.

Authors from pharmaceutical companies, or other commercial organizations that sponsor clinical trials, should adhere to the Code of Ethics for the International Medical Journal Editors, which are designed to ensure that publications are produced in a responsible and ethical manner. This applies to pharmaceutical companies or individuals that work on industry-sponsored publications, such as freelance writers, contract research organizations, and medical writers.

The involvement of medical writers or anyone else who assisted with the preparation of the manuscript content should be acknowledged in the Acknowledgements section, as described in the European Medical Writers Association (EMWA) guidelines on the role of medical writers in developing clinical trials. If medical writers are not listed among the authors, it is important that their role be acknowledged explicitly. We suggest wording such as: "The authors would like to thank [Name] for providing medical writing services on behalf of XYZ Pharmaceuticals Ltd.'".

Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available to the editorial office.

Submission of a manuscript to Journal of Carcinogenesis implies that readily reproducible materials described in the manuscript should be freely available to any scientist wishing to use them for non-commercial purposes. Nucleic acid sequences, protein sequences, and other such materials should be made available to the editorial office.

deposited in an appropriate database in time for the accession number to be included in the published article. In computational information is unacceptable for inclusion in databases because of lack of experimental validation, the sequences must be published in an article.

Any 'in press' articles cited within the references and necessary for the reviewers' assessment of the manuscript should be made available to the editorial office.

Nucleotide sequences

Nucleotide sequences can be deposited with the DNA Data Bank of Japan (DDBJ), European Molecular Biology Laboratory (EMBL) Database, or GenBank (National Center for Biotechnology Information).

Protein sequences

Protein sequences can be deposited with SwissProt or the Protein Information Resource (PIR).

Structures

Protein structures can be deposited with one of the members of the Worldwide Protein Data Bank. Nucleic Acids structures can be deposited with the Nucleic Acids Database at Rutgers. Crystal structures of organic compounds can be deposited with the Cambridge Crystallographic Data Center.

Chemical structures and assays

Structures of chemical substances can be deposited with PubChem Substance. Bioactivity screens of chemical substances can be deposited with PubChem Bioassay.

Microarray data

Where appropriate, authors should adhere to the standards proposed by the Microarray Gene Expression Data Society and make their data available to the public repositories, such as ArrayExpress, Gene Expression Omnibus (GEO) or the Center for Information Biology Gene Expression Data.

Computational modeling

We encourage authors to prepare models of biochemical reaction networks using the Systems Biology Markup Language and to deposit them in the BioModels database, as well as submitting it as an additional file with the manuscript.

Plasmids

We encourage authors to deposit copies of their plasmids as DNA or bacterial stocks with Addgene, a non-profit repository, or the plasmid repository Database at Harvard.

Preparing main manuscript text

File formats

The following word processor file formats are acceptable for the main manuscript document:

Microsoft Word (version 2 and above)

Rich text format (RTF)

Users of other word processing packages should save or convert their files to RTF before uploading. Many free tools are available.

Note that figures must be submitted as separate image files, not as part of the submitted article file.

Maximum size allowed:

First page file (Including cover letter): 100 KB

Article file: 1 MB

Article types

When submitting your manuscript, you will be asked to assign one of the following types to your article:

Research

Commentary

Review

Short paper

Please read the descriptions of each of the article types, choose which is appropriate for your article and structure it accordingly. Research articles will be classified as Research, the structure for which is described below.

Manuscript sections for Research articles

Manuscripts for Research articles submitted to Journal of Carcinogenesis should be divided into the following sections:

- Title page
- Abstract
- Background
- Methods
- Results
- Discussion
- Conclusions
- List of abbreviations used (if any)
- Competing interests
- Authors' contributions
- Acknowledgements
- References
- Figure legends (if any)
- Tables and captions (if any)
- Description of additional data files (if any)

The Accession Numbers of any nucleic acid sequences, protein sequences or atomic coordinates cited in the manuscript should include the corresponding database name; for example, [EMBL:AB026295, EMBL:AC137000, DDBJ:AE000812, GenBank:U498 PIR:S66116].

The databases for which we can provide direct links are: EMBL Nucleotide Sequence Database (EMBL), DNA Data Bank of Japan (GenBank), Protein Data Bank (PDB), Protein Information Resource (PIR) and the Swiss-Prot Protein Database (Swiss-Prot).

Title page

This should list the title of the article. The title should include the study design, for example:

A versus B in the treatment of C: a randomized controlled trial

X is a risk factor for Y: a case control study

The full names, institutional addresses, and e-mail addresses for all authors must be included on the title page. The correspon

Article file

Do not include the names of the authors, institutes or any other personal in the "Article File" or running title. The first page file page and covering letter. Acknowledgement should be included in the 'First Page' file only. You may use the templates provided files as per our instructions.

Abstract

The abstract of the manuscript should not exceed 350 words and must be structured into separate sections: **Background**, the **Methods**, how the study was performed and statistical tests used; **Results**, the main findings; **Conclusions**, brief summary minimize the use of abbreviations and do not cite references in the abstract; Trial registration, if your research article reports intervention, please list your trial registry, along with the unique identifying number, e.g. Trial registration: Current Controlled that there should be no space between the letters and numbers of your trial registration number.

Background

The background section should be written from the standpoint of researchers without specialist knowledge in that area and must illustrate - the background to the research and its aims. Reports of clinical research should, where appropriate, include a summary indicate why this study was necessary and what it aimed to contribute to the field. The section should end with a very brief statement the article.

Methods

This should include the design of the study, the setting, the type of participants or materials involved, a clear description of all the type of analysis used, including a power calculation if appropriate.

Results and Discussion

The Results and Discussion may be combined into a single section or presented separately. Results of statistical analysis should and absolute risks or risk reductions, and confidence intervals. The results and discussion sections may also be broken into sub headings.

Conclusions

This should state clearly the main conclusions of the research and give a clear explanation of their importance and relevance. included.

List of abbreviations

If abbreviations are used in the text they should be defined in the text where first used.

Competing interests

A competing interest exists when your interpretation of data or presentation of information may be influenced by your personal or professional relationships with other people or organizations. Authors should disclose any financial competing interests but also any non-financial competing interests that could cause embarrassment were they to become public after the publication of the manuscript.

Authors are required to complete a declaration of competing interests. All competing interests that are declared will be listed in the manuscript. If an author gives no competing interests, the listing will read 'The author(s) declare that they have no competing interests'.

When completing your declaration, please consider the following questions:

Financial competing interests

- In the past five years have you received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future? Is such an organization financing this manuscript (including your salary)? If so, please specify.
- Do you hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript? If so, please specify.
- Do you hold or are you currently applying for any patents relating to the content of the manuscript? Have you received or will you receive salary from an organization that holds or has applied for patents relating to the content of the manuscript? If so, please specify.
- Do you have any other financial competing interests? If so, please specify.

Non-financial competing interests

Are there any non-financial competing interests (political, personal, religious, ideological, academic, intellectual, commercial or other) that may in any way gain or lose financially from the publication of this manuscript? If so, please specify.

If you are unsure as to whether you, or one of your co-authors, has a competing interest please discuss it with the editorial office.

Authors' contributions

In order to give appropriate credit to each author of a paper, the individual contributions of authors to the manuscript should

An "author" is generally considered to be someone who has made substantive intellectual contributions to a published study. 1) have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data; 2) participated in drafting the manuscript or revising it critically for important intellectual content; and 3) have given final approval of the version to be published. All authors must have participated sufficiently in the work to take public responsibility for appropriate portions of the content. Acquisition of funding, supervision of the research group, alone, does not justify authorship.

We suggest the following kind of format (please use initials to refer to each author's contribution): AB carried out the molecular biology experiments, sequence alignment and drafted the manuscript. JY carried out the immunoassays. MT participated in the sequence alignment study and performed the statistical analysis. FG conceived of the study, and participated in its design and coordination and he authors read and approved the final manuscript.

All contributors who do not meet the criteria for authorship should be listed in an acknowledgements section. Examples of this are a person who provided purely technical help, writing assistance, or a department chair who provided only general support.

Acknowledgements

Please acknowledge anyone who contributed towards the study by making substantial contributions to conception, design, acquisition of data, or interpretation of data, or who was involved in drafting the manuscript or revising it critically for important intellectual content, or who provided technical help, writing assistance, or a department chair who provided only general support. Please also include their source(s) of funding. Please also acknowledge anyone who contributed materials essential to the study.

The role of a medical writer must be included in the acknowledgements section, including their source(s) of funding.

Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements.

Please list the source(s) of funding for the study, for each author, and for the manuscript preparation in the acknowledgement section. Please list the role of the funding body, if any, in study design; in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the preparation of the manuscript for publication.

References

All references must be numbered consecutively, in square brackets, in the order in which they are cited in the text, followed by citations should not appear in titles or headings. Each reference must have an individual reference number. Please avoid excessive numbering systems are used, the reference numbers must be finalized and the bibliography must be fully formatted before submission.

Only articles and abstracts that have been published or are in press, or are available through public e-print/preprint servers, or unpublished data and personal communications should not be included in the reference list, but may be included in the text. Obtaining permission to quote personal communications and unpublished data from the cited author(s) is the responsibility of the author. Follow Index Medicus/MEDLINE.

The references cited in the text should be after punctuation marks, in superscript with square brackets.

List the first six contributors followed by et al, do not include unnecessary bibliographic elements such as month, issue, bracketed page numbers, etc. Carefully, provide correct abbreviations for journal titles, follow the correct order of citing bibliographic elements, do not use it for references from books all the bibliographic elements should be included.

Links

Web links and URLs should be included in the reference list. They should be provided in full, including both the title of the site and the URL. Example: The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/cancer_links.html]

Journal of Carcinogenesis reference style

Article within a journal

1. Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional motifs. *Nat Genet* 1996, 13:266-267.

Article within a journal supplement

2. Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: Analysis and assessment of ab initio three-dimensional prediction of protein-protein contacts. *Proteins* 1999, 43(Suppl 3):149-170.

In press article

3. Kharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. *Eur Respir J*, in press.

Published abstract

4. Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini RN: Mesenchymal cells, stromal derived factor-1 and Arthritis Rheum 1999, 42:s250.

Article within conference proceedings

5. Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Stoneham: Butterworth-Heinemann; 1996:16-27.

Book chapter, or article within a book

6. Schnepf E: From prey via endosymbiont to plastids: comparative studies in dinoflagellates. In Origins of Plastids. Vol. 1. Stoneham: Butterworth-Heinemann; 1993:53-76.

Whole issue of journal

7. Ponder B, Johnston S, Chodosh L (Eds): Innovative oncology. In Breast Cancer Res 1998, 10:1-72.

Whole conference proceedings

8. Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Stoneham: Butterworth-Heinemann; 1996.

Complete book

9. Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University Press; 1970.

Monograph or book in a series

10. Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured Human Cells and Tissues. Edited by Harris TJR. In Methods and Perspectives in Cell Biology, vol 1. New York: Academic Press; 1995:54-56. [Stoner G (Series Editor): Methods and Perspectives in Cell Biology, vol 1.]

Book with institutional author

11. Advisory Committee on Genetic Modification: Annual Report. London; 1999.

PhD thesis

12. Kohavi R: Wrappers for performance enhancement and oblivious decision graphs. PhD thesis. Stanford University, 1999.

Link / URL

13. The Mouse Tumor Biology Database [http://tumor.informatics.jax.org/cancer_links.html]

Preparing illustrations and figures

Figures should be provided as separate files and should not be included in the main text of the submitted manuscript. Each figure should be accompanied by a legend. There is no charge for the use of color.

Formats

The following file formats can be accepted:

PNG (preferred format for photos or images)

JPG, JPEG

GIF

Maximum size allowed per image: 1 MB

Figure legends

The legends should be included in the main manuscript text file immediately following the references, rather than being a part of the figure. The following information should be provided: Figure number (in sequence, using Arabic numerals - i.e. Figure 1, 2, 3 etc); short title; and a detailed legend, up to 300 words.

Please note that it is the responsibility of the author(s) to obtain permission from the copyright holder to reproduce figures or text published elsewhere.

Patient's or institute's identity should not be revealed in the clinical photographs.

Preparing tables

Each table should be numbered in sequence using Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also have a title that is a maximum of 15 words. Detailed legends may then follow, but should be concise.

Smaller tables considered to be integral to the manuscript can be pasted into the end of the document text file, in portrait format (if a landscape page must be reformatted onto a portrait page or submitted as additional files). These will be typeset and displayed in the final manuscript. All tables should be formatted using the 'Table object' in a word processing program to ensure that columns of data are kept aligned for review; this will not always be the case if columns are generated by simply using tabs to separate text. Commas should not be used for values. Color and shading should not be used.

Larger datasets can be uploaded separately as additional files. Additional files will not be displayed in the final, published form but will be provided to the files as supplied by the author.

Tables should be self-sufficient: provide a complete title, all the abbreviations should be spelt in the footer of table. Explanatory tables. For footnotes in the table the following symbols, in this sequence: *, †, ‡, §, □, ¶, **, ††, ‡‡

Tabular data provided as additional files can be uploaded as an Excel spreadsheet (.xls). As with all files, please use the standard naming convention.

Tables should only be provided in the end of the text. Quote the table numbers at the relevant place in the text.

Preparing additional files

Although Journal of Carcinogenesis does not restrict the length and quantity of data in a paper, there may still be occasions where large datasets, tables, movie files, or other information as additional information. These files can be uploaded using the 'Additional Materials' submission process.

The maximum file size for additional files is 20 MB each, and files will be virus-scanned on submission.

Any additional files will be linked into the final published article in the form supplied by the author, but will not be displayed w available in exactly the same form as originally provided.

If additional material is provided, please list the following information in a separate section of the manuscript text, immediatel

File name

File format (including name and a URL of an appropriate viewer if format is unusual)

Title of data

Description of data

Additional datafiles should be referenced explicitly by file name within the body of the article, e.g. 'See additional file 1: Movie this analysis'.

Formats and uploading

Ideally, file formats for additional files should not be platform-specific, and should be viewable using free or widely available t suitable formats.

- Additional documentation
PDF (Adobe Acrobat)
- Movies
MOV (QuickTime)
MPG (MPEG)
- Tabular data
XLS (Excel spreadsheet)

As with figure files, files should be given the standard file extensions. This is especially important for Macintosh users, since th standard extensions. Please also make sure that each additional file is a single table, figure or movie (please do not upload lin than one sheet).

Style and language

General

Gene names should be in italic, but protein products should be in plain type.

There is no explicit limit on the length of articles submitted, but authors are encouraged to be concise. There is no restriction on the number of additional files that can be included with each article online. Figures and tables should be sequentially referenced. Authors should submit all data with each article.

Journal of Carcinogenesis will not edit submitted manuscripts for style or language; reviewers may advise rejection of a manuscript for grammatical errors. Authors are advised to write clearly and simply, and to have their article checked by colleagues before submission. Non-native speakers of English may choose to make use of a copyediting service.

Abbreviations

Abbreviations should be used as sparingly as possible. They should be defined when first used.

Typography

- Please use double line spacing.
- Type the text unjustified, without hyphenating words at line breaks.
- Use hard returns only to end headings and paragraphs, not to rearrange lines.
- Capitalize only the first word, and proper nouns, in the title.
- All pages should be numbered.
- Use the Journal of Carcinogenesis reference format.
- Footnotes to text should not be used.
- Greek and other special characters may be included. If you are unable to reproduce a particular special character, please use a description in full.

Please ensure that all special characters used are embedded in the text, otherwise they will be lost during conversion.

Units

SI Units should be used throughout (liter and molar are permitted, however).

Please note:

- Follow the standard format for original articles (Abstract, IMRAD: Introduction, Material and Methods, Results, Discussion).

- Do not divide the Material and Methods, Results and Discussion into various sub-headings.
- For review articles, include the method of literature search, along with keywords used, in abstract as well as in the intro
- Results should be more than mere enumeration of tables.